{"id":5011,"date":"2013-05-30T14:56:29","date_gmt":"2013-05-30T19:56:29","guid":{"rendered":"https:\/\/www.bad-drug.net\/?p=5011"},"modified":"2013-07-03T10:09:00","modified_gmt":"2013-07-03T15:09:00","slug":"byetta-and-januvia-lawsuits-what-went-wrong","status":"publish","type":"post","link":"https:\/\/www.bad-drug.net\/bad-drug-blog\/byetta-and-januvia-lawsuits-what-went-wrong","title":{"rendered":"Byetta and Januvia Lawsuits: What Went Wrong?"},"content":{"rendered":"

The drugs Byetta and Januvia<\/strong> have been commonly used to treat type-2 diabetes, but recent studies show their linkage to pancreatic cancer in patients using the drug for an extended period of time. Risks of pancreatic cancer and inflammation of the pancreas were known by the manufacturers, but this information was withheld from patients, causing severe adverse effects and death.<\/p>\n

The Science Behind the Pancreatic Cancer Risk<\/h2>\n

Byetta and Januvia are glucagon-like peptide-1 (GLP-1) based medications that can lower blood glucose levels by stimulating insulin secretion from pancreatic cells. They inhibit the enzyme DPP-4 to increase insulin production however this can also lead to weaker defenses against cancer since DPP-4 has been found to decrease the spread of cancer cells. A version of Byetta that is long acting can also expose users to thyroid cancer risks.<\/p>\n

Those who have taken these medications can suffer from:<\/strong><\/p>\n